Table 2.
Patient and tumour characteristics | ER+/TAM+ | ER−/TAM− | ||
N | % | N | % | |
Total | 4600 | 100 | 1359 | 100 |
Age at diagnosis | ||||
<35 | 222 | 4.8 | 182 | 23 |
35–39 | 487 | 11 | 229 | 27 |
40–44 | 1123 | 24 | 321 | 24 |
45–49 | 1668 | 36 | 385 | 28 |
50+ | 1100 | 24 | 242 | 18 |
Menopausal status at diagnosis | ||||
Premenopausal | 4600 | 100 | 1359 | 100 |
Stage at diagnosis | ||||
Stage I | 1184 | 26 | 402 | 29.6 |
Stage II | 2476 | 54 | 702 | 51.7 |
Stage III | 917 | 20 | 246 | 18.1 |
Unknown stage | 23 | 0.5 | 9 | 0.7 |
Tumour size | ||||
<2 mm | 2646 | 58 | 677 | 50 |
2≤5 mm | 1780 | 39 | 632 | 47 |
>5 mm | 156 | 3.4 | 44 | 3.2 |
Unknown | 18 | 0.4 | 6 | 0.4 |
No of metastatic lymph nodes | ||||
0 | 1704 | 37 | 695 | 51 |
1 | 1148 | 25 | 238 | 17 |
2 | 583 | 13 | 116 | 9 |
3+ | 1152 | 25 | 306 | 23 |
Unknown | 13 | 0.3 | 4 | 0.3 |
Lymph node evaluation | ||||
No | 8 | 0.2 | 3 | 0.2 |
Yes | 4592 | 100 | 1356 | 100 |
Histological grade | ||||
Unsuitable | 10 | 0.2 | 13 | 1 |
I | 955 | 21 | 21 | 1.5 |
II | 2391 | 52 | 216 | 16 |
III | 950 | 21 | 884 | 65 |
Unknown | 294 | 6.4 | 225 | 17 |
Type of primary surgery | ||||
Mastectomy | 2033 | 44 | 627 | 46 |
Lumpectomy | 2567 | 56 | 732 | 54 |
Progesterone receptor status | ||||
PR− | 383 | 8.3 | 1121 | 83 |
PR+ | 2680 | 58 | 19 | 1.4 |
Unknown/not measured | 1537 | 33 | 219 | 16 |
HER2 status | ||||
HER2− | 2887.00 | 63 | 692 | 51 |
HER2+ | 619 | 14 | 354 | 26 |
Unknown/not measured | 1094 | 24 | 313 | 23 |
Intention to treat with chemotherapy | ||||
No | 144 | 3 | 14 | 1 |
Yes | 4456 | 97 | 1345 | 99 |
Chemotherapy | ||||
No | 437 | 9 | 109 | 8 |
Yes | 4163 | 91 | 1250 | 92 |
Intention to treat with tamoxifen | ||||
No | 70 | 1.5 | 1351 | 99 |
Yes | 4530 | 98 | 8 | 0.6 |
Radiation therapy | ||||
No | 655 | 14 | 267 | 20 |
Yes | 3945 | 86 | 1092 | 80 |
Anti-HER2 therapy | ||||
No | 2887 | 63 | 692 | 51 |
Yes | 619 | 13 | 354 | 26 |
Unknown | 1094 | 24 | 313 | 23 |
Recurrence | ||||
No | 4204 | 91 | 1143 | 84 |
Yes | 396 | 8.6 | 216 | 16 |
Another malignancy | ||||
No | 4544 | 99 | 1341 | 99 |
Yes | 56 | 1.2 | 18 | 1.3 |
Dead at end of follow-up | ||||
No | 4239 | 92 | 1115 | 82 |
Yes | 361 | 8 | 244 | 18 |
Charlson Comorbidity Score | ||||
0 | 4587 | 99 | 1344 | 99 |
1 | 4 | 0.1 | 4 | 0.3 |
2 | 2 | 0 | 3 | 0.2 |
3+ | 7 | 0.2 | 8 | 0.6 |
ER, oestrogen receptor; HER, human epidermal growth factor receptor 2; ProBe CaRe, Predictors of Breast Cancer Recurrence; PR, progesterone receptor; TAM, tamoxifen therapy.